Abstract Purpose of Review Genetically engineered T cells expressing a chimeric antigen
receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution.
The progresses made in understanding its biology led to the development of targeted …

Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in
acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a …

Abstract The first CD19 CAR T-cell products, Kymriah and Yescarta, are entering the US
market and also being evaluated for marketing authorization in the EU. This breakthrough …

The clinical application of ex vivo gene edited cell therapies first began a decade ago with
zinc finger nuclease editing of autologous CD4+ T-cells. Editing aimed to disrupt expression …

Importance Remarkable progress has occurred in understanding the pathophysiology and
in developing improved personalized therapies in adult acute lymphoblastic leukemia (ALL) …

Background The administration of second-or third-generation anti-CD19 chimeric antigen
receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or …

Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal
outcomes, with survival of less than 6 months, and treatment options in the salvage setting …

Chimeric antigen receptor (CAR) modified T-cell therapy, a unique platform technology
highlighting precision medicine through utilization of molecular biology and cell-based …

Monoclonal antibodies and bispecific antibody constructs hold considerable promise in
improving the outcomes of patients with acute lymphoblastic leukemia (ALL). Antibody-drug …